Johnson & Johnson Chief Executive Officer Alex Gorsky declined to appear at a U.S. congressional hearing on the safety of the company’s Baby Powder and other talc-based cosmetics.
Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.
Paris-based Sanofi is acquiring San Diego-based immuno-oncology company Synthorx for $68 per share in cash, representing a value of $2.5 billion.
The U.S. Supreme Court turned away a novel case by Arizona seeking to recover billions of dollars that the state has said that members of the Sackler family – owners of Purdue Pharma LP – funneled out of the OxyContin maker before the company filed for bankruptcy in September 2019.
Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.
HIV-prevention advocacy group PrEP4All Collaboration filed a petition with the U.S. Patent and Trademark Office alleging that Gilead Sciences intentionally delayed the development of a safer drug for human immunodeficiency virus.
U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp.’s Brinavess said they did not believe the benefits of the heart drug outweighed the therapy’s risks, sending the company’s shares down nearly 38 percent.
Hospital groups challenged the Trump administration’s rule that requires hospitals to be more transparent about prices they charge patients for healthcare services, according to a filed lawsuit.
Johnson & Johnson said recent tests showed that Johnson’s Baby Powder was free of asbestos, after FDA investigations reported trace amounts of the material in the product earlier in 2019.
Johnson & Johnson said recent tests showed that Johnson’s Baby Powder was free of asbestos, after FDA investigations reported trace amounts of the material in the product earlier in 2019.
